NASDAQ:PACB - Pacific Biosciences of California Stock Price, Forecast & News

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Pacific Biosciences of California (NASDAQ:PACB) announced its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.19) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.04. The biotechnology company earned $21.92 million during the quarter, compared to the consensus estimate of $28.02 million. Pacific Biosciences of California had a negative net margin of 92.57% and a negative return on equity of 113.89%. View Pacific Biosciences of California's Earnings History.

Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Friday, May 1st 2020. View Earnings Estimates for Pacific Biosciences of California.

3 brokerages have issued 12-month price targets for Pacific Biosciences of California's shares. Their forecasts range from $7.00 to $8.00. On average, they expect Pacific Biosciences of California's share price to reach $7.67 in the next year. This suggests a possible upside of 117.8% from the stock's current price. View Analyst Price Targets for Pacific Biosciences of California.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pacific Biosciences of California.

News articles about PACB stock have trended very negative on Friday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pacific Biosciences of California earned a media sentiment score of -3.5 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Pacific Biosciences of California.

Pacific Biosciences of California saw a drop in short interest in the month of February. As of February 14th, there was short interest totalling 17,210,000 shares, a drop of 13.5% from the January 30th total of 19,890,000 shares. Based on an average daily trading volume, of 2,110,000 shares, the short-interest ratio is presently 8.2 days. Approximately 12.4% of the company's stock are sold short. View Pacific Biosciences of California's Current Options Chain.

Some companies that are related to Pacific Biosciences of California include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Charles River Laboratories Intl. (CRL), BIO-TECHNE (TECH), Bruker (BRKR), Cambrex (CBM), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Illumina (ILMN), Novavax (NVAX), Sangamo Therapeutics (SGMO), FireEye (FEYE), Gilead Sciences (GILD), CenterPoint Energy (CNP), Pfizer (PFE), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP) and Exelixis (EXEL).

Pacific Biosciences of California's stock is owned by a number of of institutional and retail investors. Top institutional investors include CNH Partners LLC (4.55%), Magnetar Financial LLC (4.52%), Capital International Investors (3.45%), Water Island Capital LLC (3.09%), ArrowMark Colorado Holdings LLC (2.44%) and State Street Corp (2.12%). Company insiders that own Pacific Biosciences of California stock include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes. View Institutional Ownership Trends for Pacific Biosciences of California.

PACB stock was sold by a variety of institutional investors in the last quarter, including ARP Americas LP, SG Americas Securities LLC, Havens Advisors LLC, Man Group plc, UBS Group AG, Marshall Wace LLP, Gabelli Funds LLC and Alpine Global Management LLC. Company insiders that have sold Pacific Biosciences of California company stock in the last year include James Michael Phillips, Michael Hunkapiller and Susan K Barnes. View Insider Buying and Selling for Pacific Biosciences of California.

PACB stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Farallon Capital Management LLC, Public Sector Pension Investment Board, ARK Investment Management LLC, Segantii Capital Management Ltd, Aviva PLC, Alliancebernstein L.P. and Schonfeld Strategic Advisors LLC. View Insider Buying and Selling for Pacific Biosciences of California.

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PACB stock can currently be purchased for approximately $3.52.

Pacific Biosciences of California has a market capitalization of $538.42 million and generates $90.89 million in revenue each year. The biotechnology company earns $-84,130,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Pacific Biosciences of California employs 401 workers across the globe.View Additional Information About Pacific Biosciences of California.

The official website for Pacific Biosciences of California is http://www.pacb.com/.

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]